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ABSTRACT
Lynch syndrome (LS) is characterised by the
development of colorectal cancer, endometrial cancer
and various other cancers, and is caused by a mutation
in one of the mismatch repair genes: MLH1, MSH2,
MSH6 or PMS2. In 2007, a group of European experts
(the Mallorca group) published guidelines for the clinical
management of LS. Since then substantial new
information has become available necessitating an
update of the guidelines. In 2011 and 2012 workshops
were organised in Palma de Mallorca. A total of 35
specialists from 13 countries participated in the
meetings. The first step was to formulate important
clinical questions. Then a systematic literature search
was performed using the Pubmed database and manual
searches of relevant articles. During the workshops the
outcome of the literature search was discussed in detail.
The guidelines described in this paper may be helpful for
the appropriate management of families with LS.
Prospective controlled studies should be undertaken to
improve further the care of these families.
INTRODUCTION
Lynch syndrome (LS) (previously referred to as her-
editary non-polyposis colorectal cancer; HNPCC) is
an autosomal dominant condition caused by a
defect in one of the mismatch repair (MMR)
genes.1 The syndrome is characterised by the devel-
opment of colorectal cancer (CRC), endometrial
cancer (EC) and various other cancers frequently
diagnosed at an early age. LS is probably the most
common hereditary CRC syndrome accounting for
approximately 1–3% of all CRC. It has been esti-
mated that in Europe approximately one million
individuals are carriers of an MMR defect.2
In 2007, a group of European experts (the
Mallorca group) published guidelines for the clin-
ical management of LS.3 Since then substantial
new information has become available necessitat-
ing an update of the guidelines. We used the same
approach as for the development of the previous
guidelines. In 2011 and 2012 workshops were orga-
nised in Palma de Mallorca. A total of 35 specialists
from 13 countries participated in the meeting. The
group consisted of surgeons, clinical geneticists,
molecular geneticists, pathologists, oncologists,
epidemiologists and gastroenterologists. If a par-
ticular speciality was not represented specialists
outside the group were consulted.
The first step was to formulate important clinical
questions. Then a systematic literature search was
performed using the Pubmed database and manual
searches of relevant articles. During the workshops
the outcome of the literature search was discussed
in detail. Table 1 shows the criteria that were used
for evaluation of studies, for the categorisation of
evidence that they represented and for the strength
of the recommendations that were made.
SHORT UPDATE ON LS
LS was first described by Aldred Warthin in 1913.4
In 1966, Henry Lynch reported two large families
with hereditary CRC from the midwest.5 Since
then, many hundreds of families with the same
pattern of cancer occurrence have been identified
throughout the world. In the early 1990s the under-
lying gene defect was discovered, that is, a muta-
tion in one of the MMR genes MLH1, MSH2,
MSH6 or PMS2. Recently, two groups reported that
a constitutional 30 end deletion of EPCAM, which is
immediately upstream of the MSH2 gene, may
cause LS through epigenetic silencing ofMSH2.6 7
An MMR gene defect leads through loss of the
corresponding normal alleles in the tumours of car-
riers to loss of MMR function and results in an
accumulation of mutations in (coding and non-
coding) microsatellites in such tumours (so-called
microsatellites instability; MSI). Carriers of an
MMR gene mutation have a very high risk of
developing CRC (25–70%) and EC (30–70%) and
an increased risk of developing other tumours. The
main clinical features are an early age of onset and
the occurrence of multiple tumours.
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Since 2007, many studies have been published on the risk of
developing non-CRC, non-EC cancers in carriers of an MLH1
gene mutation, MSH2 gene mutation and MSH6 gene muta-
tion.8–21 Such studies are not yet available for carriers of a PMS2
gene mutation. A summary of the findings is shown in table 2.
Those new studies also reported increased risks for pancreatic,
bladder and breast cancer and possibly prostate cancer. Notably,
carriers of MSH6 mutations appear to be particularly at risk of
gastrointestinal cancer and EC, whereas carriers of an MSH2
gene mutation have the highest cancer risks across the spectrum,
especially for the development of urinary tract cancer. The risks
for MLH1 gene mutation carriers are between the cancer risks
reported forMSH6 carriers and those forMSH2 carriers.8–21
Moreover, a recent study reported on increased cancer risks
for individuals with an EPCAM deletion.22 The investigators
compared the cancer risks between 194 carriers of an EPCAM
deletion and 473 carriers of a mutation in MLH1, MSH2,
MSH6 or a combined EPCAM–MSH2 deletion. The risk of
developing CRC for EPCAM deletion carriers was similar (75%
by age 70 years) to the risks in carriers of an MLH1 or MSH2
mutation or a combined EPCAM–MSH2 deletion but was
higher than the risk in MSH6 mutation carriers. By contrast,
the risk of EC (12% by age 70 years) was significantly lower in
female carriers of an EPCAM deletion compared to the risk in
carriers of an MSH2 or MSH6 mutation or a combined
EPCAM–MSH2 deletion. The EC risk in EPCAM deletion car-
riers was also lower than the risk in MLH1 carriers but this dif-
ference was not statistically significant.
The wide variation in cancer risk within and between families
is direct evidence that the risk is influenced by environmental
and genetic factors. In the past 5 years many genome-wide asso-
ciation studies in CRC patients have identified a total of 20 var-
iants that are associated with an increased risk of sporadic
CRC.23 A Dutch study evaluated whether six of these variants
act as modifiers of the CRC risk in 675 gene mutation carriers.24
Two variants (rs16892766 and rs3802842) were reported to
increase the CRC risk in LS, the latter only in female carriers. An
Australian group evaluated the effect of nine variants on the
CRC risk in 684 MMR gene mutation carriers.25 They confirmed
the association of the previously reported variants with CRC
risk but only for MLH1 carriers. A French group did not find an
association between these and other variants in 748 mutation
carriers.26 In summary, more studies are needed to define the
role of these variants in clinical practice.
QUESTION NO 1
How can we improve the identification of LS?
Relevant literature
Identification of individuals with LS is extremely important
because they can benefit from life-saving intensive-cancer sur-
veillance.27 However, it is the experience of most physicians
specialising in familial cancer that LS is underdiagnosed.28
Table 1 Validity and grading of recommendations
Category of evidence
Grading of
recommendations
Meta-analysis of randomised controlled trials Ia A
Randomised controlled trial Ib A
Well-designed controlled study without randomisation IIa B
Well-designed quasi-experimental study IIb B
Non-experimental descriptive study III B
Expert opinion IV C
Ta
bl
e
2
Cu
m
ul
at
iv
e
ris
k
(%
)o
fn
on
-c
ol
on
ic
an
d
no
n-
en
do
m
et
ria
lc
an
ce
rs
ac
co
rd
in
g
to
ty
pe
of
m
is
m
at
ch
re
pa
ir
ge
ne
m
ut
at
io
n
by
ag
e
70
ye
ar
s
Tu
m
ou
r
si
te
M
ut
at
io
n
ca
rr
ie
rs
M
LH
1
M
SH
2
M
SH
6
A
ll
M
F
A
ll
M
F
A
ll
M
F
A
ll
M
F
Ga
st
ric
8
9
11
–
13
17
19
0.
7/
9.
4/
0.
7
6.
2/
6.
7
2.
0/
2.
6
2.
1/
3/
5/
6/
6.
1/
10
.9
0.
2/
4.
3/
5.
2/
6/
7/
7.
8
0/
0/
0/
10
.4
Sm
al
lb
ow
el
9
11
–
13
15
19
0.
6/
2.
5/
4.
2
4.
1/
6.
1/
12
2.
7/
3.
9/
4.
1
0.
4/
4.
4/
4.
5/
7.
2/
8
1.
1/
1.
3/
4.
5/
5.
9/
8
0/
0/
0/
3
Bi
lia
ry
tra
ct
8
11
13
0.
6/
1.
4/
2
1.
9/
3
0.
02
/0
.4
0/
0
Pa
nc
re
as
11
20
0.
4/
3.
7
0
0.
7
0
Ur
in
ar
y
tra
ct
8
9
11
–
13
18
1.
9/
3.
2/
4/
8.
4
0.
2/
1.
3/
2.
8
3.
7/
15
.6
1.
1/
2.
4
2.
2/
4.
1/
12
27
.8
/1
8.
2
11
.9
/8
.4
0/
0.
7
2.
6
0
Up
pe
ru
rin
ar
y
tra
ct
12
18
19
6.
0
9.
1/
9.
4
5.
4/
6.
0
1
2.
1/
4.
8
2.
4/
0.
4
15
5.
9/
20
.3
5.
8/
9.
1
1.
5
1.
3
0
Bl
ad
de
r1
8
19
5.
5/
16
.4
1.
9/
3.
5
1
10
.8
0
8
12
.3
2.
6
1
1.
3
0
Ov
ar
ie
s8
–
13
19
6.
1/
8/
12
/1
3.
5
3.
4/
3.
9/
5/
5.
5/
6.
3/
20
7.
5/
8.
3/
10
/1
0.
4/
11
.6
/2
4
0/
1.
0/
10
Br
ai
n8
9
11
12
3.
4/
3.
7
0/
0.
3/
1.
7
1.
2/
2.
5/
6.
3
0
Pr
os
ta
te
11
12
19
9.
1/
30
0
6/
18
0/
4
Br
ea
st
12
16
19
5.
4/
14
.4
18
/1
7
1.
5/
12
13
Gut 2013;62:812–823. doi:10.1136/gutjnl-2012-304356 813
Guidelines
group.bmj.com on December 2, 2014 - Published by http://gut.bmj.com/Downloaded from 
There are many ways to improve the identification of this
syndrome that have been described in a previous report from
our group.2 For example, efforts should be aimed at increasing
the awareness of hereditary CRC in the general population and
at promoting the taking of an adequate family history in all
patients visiting a physician. However, probably the most
effective way to identify LS is via patients who are diagnosed
with CRC or EC. Many criteria have been proposed to identify
LS among these patients mainly based on age at CRC diagno-
sis, the presence of multiple tumours and the number of
affected family members. The revised Bethesda guidelines are
thus probably the most commonly used criteria to select
patients with CRC for further molecular analysis of their
tumours (MSI/immunohistochemistry).29 However, these cri-
teria and guidelines have been criticised for being too complex
and lacking in specificity and sensitivity. As a consequence, the
criteria are poorly implemented in clinical practice.
In view of these problems, systematic testing of all patients
with CRC (or all individuals with CRC <70 years) has been
recommended for loss of MMR function by means of MSI or
immunohistochemistry independent of clinical criteria.30
Since the 2007 guidelines, several studies have been published
on the outcome of testing of all patients with CRC (or indivi-
duals with CRC <70 years) (table 3).31–36 The studies showed
that this approach led to the identification of substantial
numbers of LS mutation carriers (2.4–3.7% of all tested
patients). Moreover, it was shown that many cases (12–28%)
would have been missed if the revised Bethesda criteria had
been used for selection. Two studies have shown that such an
approach is cost effective.37 38
An alternative approach to the identification of LS is by
testing unselected cases of EC for MSI and/or immunohisto-
chemistry. Two studies revealed that such an approach led to
the identification of LS in a proportion of patients (1.8–3.9%)
comparable with CRC testing39 40 (table 3). Molecular screen-
ing of EC has also been found to be cost effective.41
A recent study of molecular screening of sebaceous adenomas
and carcinomas led to the detection of LS in a subtantial pro-
portion of cases (14%).42
Due to the cascade effect, the identification of index cases by
molecular screening leads on average to the detection of three
additional relatives with LS, which demonstrates the utility of
this approach and indicates its cost effectiveness.
Conclusion and recommendation
Testing all CRC (or individuals with CRC<70 years) and all EC
(or individuals with EC<70 years) by immunohistochemistry
or MSI is useful for the identification of patients with LS (cat-
egory of evidence IIb).The Mallorca group recommends investi-
gation of all CRC (or individuals with CRC<70 years) by
immunohistochemistry of the four MMR proteins or MSI
(grade of recommendation C). These tests should be accompan-
ied by methods that identify MLH1 promotor methylation.
Investigation of all EC in individuals less than 70 years by
immunohistochemistry or MSI can be considered to improve
identification (grade of recommendation C).
QUESTION NO 2
What is the optimal colorectal surveillance protocol for LS?
Table 3 Outcome of prospective molecular screening of CRC or LS-associated cancer
Author, year
(reference) No/type of cancer Screening test Outcome
Pathogenic mutation
(%)
No of (%) mutation carriers
fullfilling revised Bethesda
guidelines
Type of
mutations
Hampel et al
(2008)31
500 CRC MSI, immunohistochemistry
MLH1-methyl.
64 MSI-H (12.8%) 18 (3.6%) 13/18 (72%) 4 MLH1
10 MSH2
3 MSH6
1 PMS2
Julie et al (2008)32 214 CRC MSI, immunohistochemistry,
BRAF, MLH1-methyl.
21 MSI-H (9.8%) 8 (3.7%) 6/8 (75%) 2 MLH1
5 MSH2
1 MSH6
van Lier et al
(2012)33
1117 CRC
≤70 years
MSI, immunohistochemistry
MLH1-methyl.
121 MSI-H (10.9%) 50 LS-like* (4.5%); 42
tested: 27 (2.4%)
mutations
20/27 (74%) 5 MLH1
5 MSH2
11 MSH6
5 PMS2
1 EPCAM
125
Advanced
adenoma≤45 years
Idem 3 (2.4%) LS-like;
3 (2.4%) mutations
N.A. 2 MLH1
1 MSH2
Moreira et al
(2012)36
10.206 CRC MSI, immunohistochemistry
MLH1-methyl.
1386 MSI-H
(13.8%)
312 (3.1%) 78/82 (88%) 34 MLH1
33 MSH2
9 MSH6
6 PMS2
Canard et al
(2012)35
1040 CRC MSI, immunohistochemistry
(partly)
MLH1-methyl.
98 MSI-H (9.4%) 25 (2.4%) 22/25 (88%) 4 MLH1
19 MSH2
2 MSH6
Hampel et al
(2006)39
543 EC MSI, immunohistochemistry
(partly)
MLH1-methyl.
118 MSI-H (21.7%) 9 (1.8%) N.A. 1 MLH1
2 MSH2
6 MSH6
2 PMS2
Leenen et al
(2012)40
179 EC
≤70 years
MSI, immunohistochemistry
MLH1-methyl.
42 MSI-H (23%) 11 (6.2%) LS-like;
7 mutations (3.9%)
N.A. 1 MLH1
2 MSH2
6 MSH6
2 PMS2
Plocharczyket al
(2012)42
36
Sebaceous
tumours
Immunohistochemistry 14 MMR-protein
loss (38.8%)
5 (14%) N.A. Not reported
*LS-like: loss of expression of MMR proteins compatible with presence of MMR gene mutation.
CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; MSI, microsatellites instability; NA, not applicable.
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Relevant literature
Colorectal surveillance is the only surveillance protocol in LS
proved to be effective.43 Regular colonoscopy leads to a reduc-
tion of CRC-related mortality and also to a significant reduc-
tion of overall mortality in contrast with CRC screening in the
general population.27
However, there is an ongoing discussion about the optimal
interval between colonoscopic examinations. Although a 3-year
interval between colonoscopies has been proved to be effect-
ive,43 there are no studies that have compared the effectiveness
between different intervals. Since 2007, three prospective
studies and one retrospective study analysing the effectiveness
of colonoscopic surveillance have been published.44–47 The char-
acteristics of the study populations, the intervals that were
recommended and the outcomes are summarised in table 4.
Unfortunately, it is difficult to compare the risks of develop-
ing an interval cancer (defined as a cancer that develops after a
negative screening examination) between the studies due to the
different methodologies used. The proportion of interval
cancers with a local tumour (stages I and II) varied from 78%
to 95%. Most tumours (57–62%) were located in the right
colon, which emphasises the importance of careful investiga-
tion of this part of the colon. In the Dutch, German and
Canadian series, most interval cancers were diagnosed in indivi-
duals older than 40 years. However, in the Finnish series a sub-
stantial proportion (20–30%) were diagnosed between the age
of 30 and 40 years. In one study, the influence of the type of
MMR gene defect on the risk of developing interval cancers
was evaluated. That study demonstrated that the risk was
lower for carriers of an MSH6 gene mutation, although the dif-
ference was not statistically significant.
In the Finnish series, it was found that mortality due to CRC
was associated with a lack of participation in the surveillance
programme. This is concerning given that the lack of compliance
with the recommended surveillance interval in the German and
Canadian studies was 20% and 42%. To guarantee the continu-
ity of surveillance and improve compliance with the surveillance
recommendations patients should be registered at a regional or
national hereditary cancer registry. Such registries can improve
participation in surveillance by using reminder systems.48
Conclusion
A 3-year interval between colonoscopies has been proved to be
effective (category of evidence IIb). In view of the observation
of (advanced) CRC detected between 2 and 3 years after sur-
veillance colonoscopy, the recommended interval for mutation
carriers is 1–2 years (grade of recommendation C).
QUESTION NO 3
How effective is surveillance for endometrial and ovarian cancer?
Relevant literature
In LS, the risk of developing EC is very high and equals or even
exceeds the risk of CRC in female gene carriers.49 The overall
prognosis of patients diagnosed with EC is relatively good,
with a 10-year survival of approximately 80%. However, 20%
of the patients will ultimately die from the disease. Moreover, a
substantial proportion of patients need treatment with radi-
ation and/or chemotherapy.
The main goal of surveillance for EC is detection and treat-
ment of premalignant lesions (ie, endometrial hyperplasia) or EC
at an early stage and thereby improving the prognosis for the
patients. The World Health Organization classifies endometrial
hyperplasia as simple or complex determined by the degree of
architectural abnormality, and as having or not having atypia.
Nieminen et al50 studied serial specimens of normal endomet-
rium, simple hyperplasia and complex hyperplasia with and
without atypia during 10 years of surveillance. MMR deficiency
was observed in 7% of normal endometrium, 40% of simple
hyperplasia, 100% of complex hyperplasia without atypia and
92% of complex hyperplasia with atypia, suggesting that in LS,
contrary to the traditional view, complex hyperplasia with and
without atypia was equally important as precursor lesions of EC.
In 2011, Auranen and Joutsiniemi51 performed a systematic
review of all studies that addressed gynaecological cancer sur-
veillance in women who belonged to LS families. The authors
identified five studies in the literature that included a total of
647 women.52–56 The screening methods applied in the studies
varied from only transvaginal (or transabdominal) ultrasound
(two studies) to a combination of transvaginal ultrasound and
endometrial biopsy (two studies) and hysteroscopic endomet-
rial biopsy (one study). The intervals between examinations
varied between 1 year in three studies, 1–2 years in one study
and 2–3 years in another study. In the studies that used only
ultrasound as the screening tool, no EC were detected and only
interval cancers occurred. However, in the studies with a proto-
col that also included endometrial biopsies, the detection of
premalignant lesions and EC was improved.
Renkonen-Sinisalo et al54 compared the Federation of
Gynecology and Obstetrics (FIGO) stages of the screen-
detected cancers with those of EC diagnosed after presentation
of signs or symptoms. Although less advanced cancers were
observed in the screen-detected group, the difference was not
statistically significant. The main advantage of the surveillance
programme seems to be the identification of precursor lesions.
No benefit was shown for ovarian cancer surveillance. Auranen
and Joutsiniemi51 concluded that the available studies do not
adequately allow for evidence-based clinical decisions.
Since that review, another retrospective study was published
on the impact of gynaecological screening in MSH2 carriers
(n=54).57 Nine women were diagnosed with EC, five of which
were within 1 year of the previous negative screening test
Table 4 Outcome of colonoscopic surveillance in LS
Author/year
No of
participants
Mean follow-up
(years)
Interval recommend
(years)
Risk interval cancer*
No of interval
cancers
Location right
colon (%)
Local stage
(stage I &
II) (%) Death CRC
By follow-up
time
By age
60 years
Mecklin et al
(2007)44
420 6.7 2 – M 35%
F 22%
26 57 80 5
Engel et al (2010)46 1126 3.7 1 – – 25 Not reported 95 Not
reported
Vasen et al (2010)45 745 7.2 1–2 6%/10 years – 33 62 83 0
Stuckless et al
(2011)47
109 Ca 10 1–2 – – 21 62 78 1
*Defined as CRC that develops after a negative screening colonoscopy.
CRC, colorectal cancer; LS, Lynch syndrome.
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(transvaginal ultrasound and/or endometrial biopsy) and two
were at initial screening. Of the nine EC, seven were localised
cancers (stage I), and one was at an advanced stage (stage III).
There were no deaths due to EC. Six women had ovarian
cancer, three of which were within 1 year of a previous normal
screening. Two died from ovarian cancer. The authors con-
cluded that gynaecological screening did not result in earlier
detection of gynaecological cancer.
In view of the uncertain effect of the surveillance pro-
gramme, it is important to consider possible disadvantages of
the programme. Elmasry et al58 assessed the patient acceptabil-
ity of the available screening modalities. Transvaginal ultra-
sound was associated with less discomfort than hysteroscopy
or Pipelle biopsy. There was no significant difference between
the pain scores for hysteroscopy and Pipelle biopsy. Huang
et al59 compared a new patient-centered approach by combin-
ing endometrial biopsies and colonoscopy under sedation. This
approach was much more acceptable than an endometrial
biopsy as a single procedure without sedation.
Wood et al60 evaluated the effect of gynaecological screening
in LS families on psychological morbidity. The authors did not
demonstrate any adverse psychological effect in the screened
population, even in those with false positive screening results.
Conclusion
The value of surveillance for EC is still unknown. Surveillance
of the endometrium by gynaecogical examination, transvaginal
ultrasound and aspiration biopsy starting from the age of
35–40 years may lead to the detection of premalignant disease
and early cancers (category of evidence III) and should be
offered to mutation carriers (grade of recommendation C). The
pros and cons should be discussed (table 5). Given the lack of
evidence of any benefit, gynaecological surveillance should pref-
erably be performed as part of a clinical trial.
QUESTION NO 4
What is the role of prophylactic hysterectomy with or without
oophorectomy?
Relevant literature
Schmeler et al61 have shown in a retrospective study that
prophylactic hysterectomy and oophorectomy is very effective
in LS: none of the patients who underwent prophylactic
surgery (61 out of 315) developed endometrial or ovarian
cancer, whereas 33% of patients who did not have surgery
developed EC and 5.5% developed ovarian cancer.
A recent study documented two cases of LS patients who
developed primary peritoneal cancers after prophylactic
surgery.62 A cost-effectiveness analysis of prophylactic surgery
versus gynaecological screening showed that risk-reducing
surgery was associated with both the lowest costs and highest
number of quality-adjusted life years.63 64
In view of the very high risk of EC, the substantial propor-
tion of women who will die from the disease, the morbidity
associated with treatment and the effectiveness of prophylactic
surgery, there is agreement that the option of prophylactic hys-
terectomy should be discussed with mutation carriers who
have completed their family. However, there are still some
important questions that should be addressed.
First, should prophylactic surgery include salpingo-
oophorectomy? The risk of developing ovarian cancer in muta-
tion carriers is approximately 9% with the highest risks inMLH1
and MSH2 mutation carriers and the lowest risk inMSH6 muta-
tion carriers. Although the prognosis of unselected patients with
ovarian cancer (and also of patients with ovarian cancer asso-
ciated with BRCA1 and BRCA2 mutations) is very poor, recent
studies suggested that the biology of ovarian cancer associated
with LS may be different. Three studies showed that the major-
ity of symptomatic ovarian cancers (77–81%) in LS are diagnosed
at an early stage (FIGO stages I and II).65–67 In a multicentre
study, Grindedal et al66 collected a large number (n=144) of pro-
spectively diagnosed cases of ovarian cancer and demonstrated a
very good prognosis with a 10-year survival of 81%.
Prophylactic surgery in postmenopausal women should
include salpingo-oophorectomy. However, salpingo-oophorec-
tomy in premenopausal women is associated with various
adverse effects such as an immediate onset of menopause as a
result of oestrogen deprivation potentially resulting in vaso-
motor symptoms and possible sexual dysfunction. Oestrogen
deprivation may also lead to a higher risk of osteoporosis. A
large study by Madalinska et al68 in 846 carriers of a BRCA1 and
BRCA2 mutations reported significantly more endocrine symp-
toms in the patients who underwent prophylactic oophorec-
tomy compared to women who underwent surveillance of the
ovaries. No significant differences were observed in the level of
sexual activities between the two groups, but women in the
prophylactic surgery group reported significantly more discom-
fort (vaginal dryness and dyspareunia), less pleasure and less sat-
isfaction during sexual activities. Despite this, the study did not
reveal any other differences in quality of life. Usually, hormone
replacement therapy is prescribed in premenopausal women
after salpingo-oophorectomy, which may partly reduce the
vasomotor symptoms but has no effect on sexual discomfort.69
In view of the recent study that suggests a relatively good
prognosis of ovarian cancer in LS, it is questionable whether
the possible small gain in life expectancy outweighs the adverse
effects of prophylactic salpingo-oophorectomy at a young age.
The second question is how these issues should be discussed
with the patient and how the patient can be supported in their
decision-making? The best approach is to inform the patient
Table 5 Pros and cons of surveillance for gynaecological cancer
Pros Cons
Identification of precursor lesions of
endometrial cancer
Small risk of death
Identification of early stage
endometrial cancer (not proved)
Physical burden of surveillance examination
especially Pipelle biopsy
No evidence of efficacy for early stage
ovarian cancer detection
Psychological burden
Table 6 Pros and cons of prophylactic hysterectomy with and without
salpingo-oophorectomy
Pros Cons
Prevention of endometrial and
ovarian cancer
Small risk of death
Prevention of morbidity
related to treatment
Mortality surgery (0.1%)
Morbidity surgery (5–9%)
Pelvic surgery makes colonoscopy more difficult and
painful and may reduce chance of full colonoscopy
Psychosocial problems (10–20%)
Early menopause depending of age at surgery
Sexual problems related to hysterectomy and early
menopause
Probably very small risk of developing primary
peritoneal carcinoma after oophorectomy
Unnecessary removal
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fully about all pros and cons of prophylactic surgery. As a basis
for this discussion, the pros and cons are summarised in
table 6. Depending on the type of information, a gynaecologist,
geneticist, clinical psychologist or other specialists should be
involved. Ideally, this information should also be available in
written form.
The third question is from which age surgery should be recom-
mended. The risk of endometrial and ovarian cancer increases
from the age of 40 years. The optimal timing of prophylactic
surgery, therefore, would be around the age of 40 years.
Conclusion
Hysterectomy and bilateral oophorectomy largely prevents the
development of endometrial and ovarian cancer (category of
evidence III) and is an option to be discussed with mutation
carriers who have completed their families especially after the
age of 40 years (grade of recommendation C). Also, if CRC
surgery is scheduled, the option of prophylactic surgery at the
same time should be considered. All pros and cons of prophy-
lactic surgery should be discussed.
QUESTION NO 5
What is the effectiveness of surveillance for other cancers?
Gastric cancer
In LS, the cumulative risk of developing gastric cancer by the
age of 70 years is approximately 5%. Recent studies have
shown that there is no evidence for the clustering of gastric
cancer in specific LS families.17 70
In parts of the world with a high background incidence of
gastric cancer in the population (Korea, Japan), the risk of devel-
oping gastric cancer in LS families is also higher, suggesting the
role of environmental factors. Although not proved, the impres-
sion exists that the incidence of gastric cancer in LS in the
western world seems to be decreasing in parallel to the declining
incidence of gastric cancer in the general population.17
The prognosis in unselected patients with cases of gastric
cancer is poor, with an average 5-year survival rate of 20–25%.
According to the Lauren’s classification, tumours are separated
into ‘diffuse’, ‘intestinal’ and ‘mixed’ types.71 In ‘high inci-
dence’ areas, patients with Helicobacter pylori-associated chronic
gastritis may develop atrophy followed by intestinal metaplasia
over time. This may culminate in neoplastic changes, especially
adenocarcinoma of ‘intestinal’ type. Two studies showed that
the majority of gastric cancer associated with LS is of the intes-
tinal type (73–79%).17 72 The goal of surveillance for gastric
cancer would be the detection of precursor lesions and gastric
cancer at an early curable stage. It is well known that early
detection of diffuse gastric cancer is extremely difficult, and for
this reason prophylactic gastrectomy is recommended in car-
riers of a CDH1 mutation. However, as most cancers in LS are
of the intestinal type, regular upper gastrointestinal endoscopy
may lead to the early detection of precursor lesions and early
cancer. Indeed, a Finnish study reported potential precursor
lesions in a substantial proportion of 73 MMR gene mutation
carriers: H pylori infection was observed in 26%, atrophy in
14% and intestinal metaplasia also in 14%.73 There are no
(other) studies in the literature that have evaluated the effect-
iveness of surveillance for gastric cancer. In view of the rela-
tively low risk of gastric cancer and the lack of established
benefit, the Mallorca group does not advise surveillance for
gastric cancer. On the other hand, the Mallorca group recom-
mends screening mutation carriers for the presence of an H
pylori infection and subsequent eradication if detected. In
countries with a high incidence of gastric cancer in LS, surveil-
lance might be performed in a research setting.
Cancer of the small bowel
The risk of developing this cancer in carriers of an MLH1 or
MSH2 mutation is approximately 5%. In carriers of a MSH6
mutation, small bowel cancer is relatively rare. There is no evi-
dence for the clustering of small bowel cancer in specific fam-
ilies.12 The tumours in LS families are mainly located in the
proximal small bowel (43%) and the jejunum (33%); 7% are
located in the ileum.15 Patients with small bowel cancer have a
poor prognosis. The 5-year survival rate is 30–35%.
A French study recently compared the use of CTenteroclysis
and video-capsule endoscopy in 35 mutation carriers.74
Video-capsule endoscopy detected three (10%) lesions of which
two were missed by CT enteroclysis. The lesions included two
adenomas and one jejunal cancer. Although the yield of this
small study is noteworthy, more studies are needed to confirm
the findings and to assess the cost effectiveness. Currently, the
Mallorca group does not recommend surveillance for this
cancer. As small bowel cancer is frequently located in the duo-
denum and ileum, we suggest inspection of the distal duode-
num during upper gastrointestinal endoscopy (if performed)
and also of the ileum during colonoscopy.
Cancer of the urinary tract
Many studies have reported an increased risk of urothelial
cancers of the upper urinary tract in LS. Recent studies have
also demonstrated an increased risk of bladder cancer.18 19 75
The estimated risk varies from 5% to 20%, with the highest
risk in male carriers and those with an MSH2 mutation. The
risk for non-urothelial tumours was not increased.
The classic presenting sign of urothelial tumours is haematuria
without pain. The prognosis of patients with urothelial tumours
depends on the stage and grade of the tumours. The 5-year sur-
vival of non-invasive, low grade cancers is over 90%, while for
those with high grade cancers, it is 60–70%. Periodic examination
may lead to the detection of cancers at earlier stages.
Options for urinary tract cancer screening include dipstick
testing of the urine for microscopic haematuria, urine cytology,
screening for tumour-specific molecular markers in the urine and
abdominal ultrasound. Cystoscopy is the gold standard for
bladder cancer detection. However, although flexible cystoscopy
has a high sensitivity and positive predictive value, it is not con-
sidered appropriate for screening in the general population or high-
risk groups due to its cost, procedural nature, and (small) risks.
Urothelial carcinoma in the sporadic setting is known to be
associated with tobacco, aryl amines and other chemical carci-
nogens. Urine cytology and cystoscopy have been used to screen
workers who are at extremely high risk of developing bladder
cancer through occupational exposure to known urothelial carci-
nogens. Although several non-randomised studies have docu-
mented a high incidence of bladder cancer in populations with
heavy exposure to such carcinogens, they have not demonstrated
that active screening alters the natural history of the disease in
those who do develop bladder cancer.76–79
One Danish study has evaluated the effectiveness of surveil-
lance of the urinary tract in LS.80 The study reviewed records
of 3411 relatives from LS families (n=263), or families that met
the Amsterdam criteria I or II (n=426) or that had been sus-
pected of LS (n=288).
The authors collected results of urine cytology from the
National Danish Pathology Database. A total of 977 patients
had 1868 screening procedures involving a total of 3213 person
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years (median 2.8 years, range 0–11.5). In two patients (0.1%),
the screening led to the identification of asymptomatic urinary
tumours (two small non-invasive bladder cancers). During the
study 14 patients (of the 997) developed a urinary cancer, includ-
ing five interval cancers. The tumours consisted of seven bladder
cancers without invasion, four bladder cancers with invasion,
one renal pelvis tumour with invasion and one renal pelvis
tumour without invasion and one renal cell carcinoma. The sen-
sitivity of urine cytology was 29% in diagnosing asymptomatic
tumours. The corresponding specificity was 96%. Eleven out of
the 14 tumours were diagnosed inMSH2 families.
The authors concluded that urine cytology is not an appro-
priate screening method of screening for urinary tract cancer in
LS. The study does not allow any conclusion to be made about
the benefit of surveillance in subgroups of families (eg, those
with the MSH2 mutation). Although abdominal ultrasound
has been recommended as a surveillance tool in LS, there are no
reports on its effectiveness.
In view of the lack of evidence for the benefit of surveillance
for urinary tract cancer, the Mallorca group does not recom-
mend surveillance for urinary tract cancer in LS outside the
setting of a research project.
Prostate cancer
Prostate cancer is the most common cancer in men. The progno-
sis of these tumours is relatively good, with a 10-year survival of
all men with prostate cancer of 72%. Previous studies did not
show a (significantly) increased risk of prostate cancer in men
with LS11 75 However, three recent studies did reveal an
increased risk of developing this cancer in LS. A study by Engel
et al19 reported a significantly increased risk of prostate cancer in
LS (17 cases in 1011 male mutation carriers; standardised inci-
dence ratio (SIR) 2.5 (1.4–4)). The highest risk was found in car-
riers of a MSH2 mutation (cumulative risk by the age of
70 years: MSH2: 18%; MLH1: 0%; MSH6: 4%). Another study
reported a tenfold increased risk of prostate cancer in carriers of
a MSH2 mutation (four cases in 130 male mutation carriers)
but the cumulative risk by the age of 70 years was only 6%.21 In
the third study from Norway, out of 106 male carriers or obli-
gate carriers of MMR mutations, nine had developed prostate
cancer16 (six in MSH2 carriers). Immunohistochemical analysis
showed the absence of the corresponding MMR gene product in
seven of eight available tumours. The number of men with a
Gleason score between eight and 10 was significantly higher
than expected. Kaplan–Meier analysis suggested that cumulative
risk by 70 years in MMR mutation carriers may be 30% (SE
0.088) compared to 8.0% in the general population.
Prostate-specific antigen screening of the general population is
generally not recommended due to the serious side-effects of treat-
ment and the indolent course of most screen-detected cancers.
If the increased risk of prostate cancer and the development
of aggressive tumours are confirmed in further studies of LS
families, male gene carriers, especially of an MSH2 mutation
might benefit from surveillance.
Until more studies are available, the Mallorca group does not
recommend surveillance for prostate cancer in LS families
outside of appropriate research studies (see http://impact-study.
co.uk).
Pancreatic cancer
Recent studies have revealed an increased risk of developing
pancreatic cancer in LS. Kastrinos et al20 reported a RR of 8
across 147 families with an MMR gene mutation, and calcu-
lated a cumulative risk of 3.7% by the age of 70 years. Win
et al75 studied 446 MMR mutation carriers and reported a SIR
of 11 for pancreatic cancer. The prognosis of patients with pan-
creatic cancer is very poor, with an average life expectancy of
6 months after diagnosis.
However, the benefit of surveillance for pancreatic cancer in
high-risk groups is unknown and as the reported absolute risk
is relatively low, the Mallorca group does not recommend sur-
veillance for this cancer in LS families outside the setting of a
research programme.
Breast cancer
Whether breast cancer is part of the tumour spectrum of LS is
controversial.8 81 82 Loss of MMR function has been reported in
a substantial proportion of breast cancers in LS.83 84 In a large
study by Watson et al,12 the risk of breast cancer was not
increased (5.4% by age 70 years). In contrast, two recent
studies reported increased risks of developing breast cancer.
Barrow et al11 reported an increased risk only in MLH1 carriers
(18%). A large cohort study from the German and Dutch LS
registry reported a significantly increased risk for developing
breast cancer.19 The cumulative risk by the age of 70 years was
14% in all female carriers, with the highest risk in MLH1 car-
riers (MLH1: 17%; MSH2: 14.4%; MSH6: 11%). The risk of
developing breast cancer started to increase after the age of
40 years. Win et al75 reported a SIR of 3.95 for breast cancer in
the follow-up of a cohort of 446 unaffected carriers of a MMR
gene mutation.
Further studies are needed to confirm these results and deter-
mine whether the increased risk is restricted to MLH1 muta-
tion carriers. At present, female carriers of an MMR gene
mutation should be advised to participate in population screen-
ing programmes for breast cancer (biannual mammography
from the age of 45 or 50 years).
General conclusion
A recent analysis on the causes of deaths in LS revealed that a
large proportion (61%) of the cancer deaths were now asso-
ciated with non-CRC non-EC.85 Unfortunately, the benefit of
surveillance for most extracolonic cancers is still unknown.
Surveillance for these cancers should therefore only be per-
formed in a research setting. The results of long-term surveil-
lance should ideally be collected and evaluated at a regional or
national or international LS registry.
To ensure informed decision-making about surveillance by
patients, all pros and cons of such programmes should be dis-
cussed with the patient. If surveillance is offered, patients
should understand that there is uncertainty about the potential
benefits sand harms. Table 7 shows the protocol recommended
by the Mallorca group.
QUESTION NO 6
What is the appropriate surgical treatment for CRC?
Relevant literature
In LS, the risk of developing a second CRC after partial colec-
tomy for primary CRC has been reported to be approximately
16% at 10 years follow-up despite close surveillance.86 87 In
view of this risk, more extensive treatment (total or subtotal
colectomy) of the primary CRC might be considered. However,
for decision-making it is important to address the following
questions to determine the benefit of the patient: what is the
risk of developing a second cancer under appropriate (post-
operative) surveillance; and what is the effect of more extensive
surgery on the functional outcome and quality of life.
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Three recent studies reported the risk of developing an inter-
val CRC under colonoscopic surveillance.44–46 In one study, a
risk of 6% after 10 years of follow-up was reported.45 In the
other studies, the risk of developing CRC by the age of 60 years
was between 22% and 35% depending on sex and surveillance
interval.44 46 One study especially evaluated the functional
outcome and quality of life after limited and extensive surgery
in LS patients.88 Although the functional outcome was signifi-
cantly worse after extensive surgery, quality of life was similar
in both groups.
Conclusion
In view of the substantial risk of a second CRC after partial
colectomy (category of evidence III) and similar quality of life
after partial and subtotal colectomy (category of evidence III),
the option of subtotal colectomy including its pros and cons89
should be discussed with all LS patients with CRC, especially
younger patients (grade of recommendation C).
QUESTION NO 7
What is the influence of environmental and lifestyle factors on
the development of adenoma or CRC in LS?
Relevant literature
There is ample evidence that the risk of developing cancer in LS
is influenced by environmental factors. The tumour spectrum
observed in the first LS syndrome family published in 1913 by
Warthin4 included mainly gastric cancers and EC. Follow-up
reports of this well-known family showed that in the current
generations CRC was now the most common tumour.90 The
changes reflect the decrease of gastric cancer and increase of
CRC in the general population in western countries.
In addition, the spectrum of cancers in LS reported in Japan
and South Korea also differs from the spectrum found in LS
families in western countries, with more gastric cancers
reported in families from eastern Asia.91
An important question is which environmental and lifestyle
factors influence the development of cancer in LS. In the past
decade a large number of studies have been published
that addressed this question. The studies are summarised in
table 8.92–99
Four studies showed that smoking was associated with a
higher risk of developing colorectal neoplasias. In addition, two
studies demonstrated that a higher body mass index (BMI) was
associated with an increased risk of colorectal neoplasia.
Alcohol (two out of three studies) was not associated and fruit
and fibre intake was possibly related to decreased risks. A
recent large randomised controlled trial showed that resistant
starch (a component of dietary fibre) had no effect on the
development of CRC in LS.100 Another study investigated the
effect of various dietary patterns on the development of aden-
omas in LS.99 A ‘snack’ dietary pattern was associated with a
higher risk of adenoma development.
Conclusion
Smoking and a high BMI increase the risk of developing aden-
omas and CRC in LS (category of evidence IIb). Patients are
advised to stay within the normal weight range and refrain
from smoking (grade of recommendation B).
QUESTION NO 8
What is the role of aspirin in the management of LS?
Relevant literature
The CAPP2 trial randomly assigned 1009 LS carriers to two
tablets (600 mg) of enteric-coated aspirin daily for 2–4 years.
The overall burden of adenomas and carcinomas at the end of
the intervention phase was unchanged,101 but re-analysis when
the first recruits reached the planned long-term follow-up
target of 10 years revealed a significant reduction in CRC and
other cancers among those randomly assigned to aspirin versus
Table 7 Surveillance protocol in LS
Site of
cancer
Lower age
limit (years) Examination
Interval
(years)
Colorectum 20–25 Colonoscopy 1–2
Uterus/
ovaries
35–40 Offer gynaecological examination,
transvaginal ultrasound, aspiration
biopsy, discuss pros and cons
1–2
Stomach 30–35 Upper gastrointestinal endoscopy only
recommended in LS families from
countries with high incidence of gastric
cancer, preferably in research setting;
Screening of all carriers >25 years for
H pylori infection
1–2
Urinary tract 30–35 Surveillance (by urine cytology and
ultrasound) of MSH2 carriers only in
research setting or if results are
systematically collected by LS registry
1
LS, Lynch syndrome.
Table 8 Outome of studies on the effect of environmental factors on the risk of adenomas and CRC in LS
Author/year Type of study No of participants
Environmental
factor Endpoint Outome
Voskuil et al (2002)92 Case–control 62 Cases
83 Controls
Meat Adenomas No association
Diergaarde et al
(2007)93
Case–control 145 Cases
103 Controls
Alcohol/smoking Adenomas Increased risk
Fruit/fibre Adenomas Decreased risk
Watson et al (2004)94 Retrospective analysis 360 Carriers Smoking CRC Increased risk
271 Carriers Alcohol CRC No association
Pande et al (2010)95 Retrospective analysis 752 Carriers Smoking CRC Increased risk
Botma et al (2010)96 Prospective cohort study 468 Carriers BMI Adenomas Increased risk in males
Win et al (2011)97 Retrospective analysis 1324 Carriers 1219
Non-carriers
BMI CRC Increased risk
Winkels et al (2012)98 Prospective cohort study 468 Carriers Smoking Adenomas Increased risk
Alcohol Adenomas No significant association
Mathers et al (2012)100 Randomised controlled
trial
918 Carriers Resistant starch CRC No effect
Botma et al (2012)99 Prospective cohort study 468 Carriers Dietary patterns Adenomas With ‘snack’ dietary pattern* increased risk of
adenomas
*‘Snack’ dietary pattern: high intake of chips, fried snacks, fast food snacks, spring rolls, mayonaise based sauces, cooking fat and butter, peanut sauce, ketchup, sweets and soda water.
BMI, body mass index; CRC, colorectal cancer; LS, Lynch syndrome.
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those randomly assigned to placebo. The study remained
double blind.102 Forty-eight participants developed 53 primary
CRC (18 recruits with 19 CRC/427 randomly assigned to
aspirin, 30 recruits with 34 CRC/434 assigned to aspirin
placebo). Intention-to-treat analysis of the time to first CRC
showed a HR of 0.63 (95% CI 0.35 to 1.13, p=0.12). Poisson
regression taking account of the multiple primary events gave
an incidence rate ratio (IRR) of 0.56 (95% CI 0.32 to 0.99,
p=0.05). The primary endpoint of the trial was the number,
size and stage of CRC after 2 years aspirin treatment. This ‘per
protocol’ analysis yielded a HR of 0.41 (95% CI 0.19 to 0.86,
p=0.02) and an IRR of 0.37 (95% CI 0.18 to 0.78, p=0. 008).
Secondary analysis revealed fewer LS-related cancers in those
on aspirin for at least 2 years (IRR 0.42, 95% CI 0.25 to 0.72,
p=0.001). There was a negative association of LS cancer inci-
dence with the numbers of aspirin taken (p=0.002). In other
words, the more aspirin someone had taken, the greater was
the reduction in cancers developed in the gastrointestinal tract
and elsewhere.
A meta-analysis conducted by Rothwell et al103 included a
total of eight randomised trials on the prevention of vascular
disease (seven placebo controlled) that examined daily aspirin
use with an initial aspirin treatment period of at least 4 years).
Using cancer registry data the impact on subsequent cancer
incidence and mortality was investigated. Among the eight
trials, with a total of 25 570 patients and 674 cancer-related
deaths, aspirin treatment using doses between 75 and 1200 mg
per day was associated with a 21% lower risk of death from
any cancer during the in-trial follow-up period. Among those
with data on cancer site, patients randomly assigned to aspirin
had a reduced risk of CRC mortality that approached statistical
significance (HR 0.41; 95% CI 0.17 to 1.00), an effect that
became apparent 5 years after the initiation of aspirin treat-
ment. The review suggested there was no greater benefit with
doses higher than 75 mg per day, although adverse effects in
the gut increased with higher doses. A dose inferiority trial,
CaPP3, will start in 2013. Combining the available data, the
recommendation is that all LS gene carriers should consider
regular daily aspirin starting with their regular surveillance and
that, when available, they should consider helping with studies
to determine the optimal dose.
The importance of testing for H pylori and subsequent eradi-
cation if detected has already been discussed in the section on
surveillance for gastric cancer (see question 5). Before starting
aspirin, eradication of H pylori may also be beneficial because it
may decrease the risk of upper gastrointestinal tract injury,
especially in those carriers with a history of peptic ulcer or
complications.104
Conclusion
Regular aspirin significantly reduces the incidence of cancer in
LS (category of evidence Ib).
The optimal dose will be determined by further randomised
studies. Given the lack of additional benefit revealed in the
meta-analyses of follow-up data from former ‘vascular ’ trials, a
reasonable inference is that the option of taking low-dose
aspirin should be discussed with gene carriers, including the
risks, benefits and current limitations of available evidence (cat-
egory of evidence IIb).
QUESTION NO 9
What is the role of prenatal diagnosis (PND) and preimplanta-
tion genetic diagnosis (PGD) in LS?
Relevant literature
For some individuals, learning that they have LS may have
implications for reproductive decision-making. In some cases,
this knowledge impacts on the timing of decisions about
having children—for example, because of their desire to have
children before pursuing prophylactic salpingo-oophorectomy.
In addition, some men and women planning on having children
in the future may have concerns about possibly passing the
genetic risk of LS-related cancers to their children.
Individuals with LS should be adequately counselled about
the risk of transmitting their hereditary predisposition to their
future children and regarding their options for PND and PGD,
including a complete discussion about the legal, practical and
psychological aspects of these decisions and also the availability
in various countries.105
PND is a technique that is performed in early pregnancy. If
the family mutation is detected, abortion can be offered. PGD
is a technique that always takes place in conjunction with
assisted reproduction (in-vitro fertilisation; IVF). Following a
succesful IVF procedure, one to two cells from the blastocyst
can be tested for the family mutation. Only those embryos
without the relevant mutation are selected for placement in
the uterus.
Dewanwala et al106 recently reported that of patients found
to carry a gene mutation associated with LS, 42% would con-
sider using prenatal testing and one in five women would con-
sider having children earlier in order to proceed with
prophylactic surgery to reduce their risk of developing gynaeco-
logical cancers. In addition, the majority of individuals under-
going genetic testing for LS felt that it would be ethical to
offer prenatal genetic testing, either PND or PGD, to those
with pathogenic MMR gene mutations. Interestingly, while
most of the subjects in their study believed prenatal testing
would be ethical, only a minority would consider it themselves.
These facts reinforce the idea that decisions regarding childbear-
ing are very personal ones and may be influenced by an indivi-
dual’s personal and family history of cancer.
Conclusion and recommendation
Cancer geneticists and genetic counsellors should be prepared
to discuss the option of PND and assisted reproductive tech-
nologies during genetic counselling of individuals with LS who
are of childbearing age (grade of recommendation C).
QUESTION NO 10
What are the psychosocial implications of genetic testing and
surveillance?
Relevant literature
Many studies have evaluated the psychological distress of
genetic testing for LS. Most studies showed that immediately
after disclosure of the test result, distress significantly increases,
but decreases again after 6 months.107–113 Long-term studies
have demonstrated that post-result increases in distress return
to baseline by 1–3 years.114–116 However, a substantial subgroup
may experience adjustment problems.107 115
The psychological implications of surveillance for hereditary
cancer has recently been reviewed by Gopie et al.117 In general,
normal psychosocial functioning was reported in LS families,
and a percentage comparable to the normal general population
(10%) had clinically relevant distress levels. However, indivi-
duals with a higher cancer risk perception, decreased vitality,
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lower general mental health status and more anxiety are at risk
of developing psychological problems.118–120
In a Swedish study on 240 individuals at high risk of CRC
(including MMR gene mutation carriers, HNPCC family
members and individuals with familial CRC) evaluation of the
quality of life using SF-36 (five of eight scales) showed generally
normal levels but lower levels regarding mental health and vital-
ity compared with the reference population.119 A study from
the Danish HNPCC register demonstrated that living with the
knowledge of LS has limited impact on self-concept.121
Three studies evaluated the experience of patients undergo-
ing colonoscopies. The studies showed that a substantial pro-
portion of these patients (30–60%) considered undergoing
colonoscopies as unpleasant, painful and frightening.59 118 122
After being counselled about genetic test results, index patients
play an important role in the communication of information
regarding LS, the gene defect in the family and the preventive
measures. Aktan-Collan et al123 investigated how parents with LS
share knowledge of genetic risk with their offspring. The study
reported that out of 248 mutation carriers with children, 87%
reported disclosure and 13% non-disclosure. Reasons for non-
disclosure were mainly the young age of offspring, socially
distant relationships, or a feeling of difficulty in discussing the
topic. The most difficult communication aspect was discussing
cancer risk with offspring. One third of the parents suggested
that health professionals should be involved in passing on this
information and that a family appointment at the genetic clinic
should be organised at the time of disclosure. The authors con-
cluded that it is a great challenge to improve the communication
processes, so that all offspring get information that is important
for their healthcare and parents get the professional support they
desire at the time of disclosure to their children.
Recommendation
Professionals should be aware of the potential psychosocial pro-
blems before and after genetic testing and during follow-up and
surveillance visits. People with increased psychological distress
should be offered referral to a clinical psychologist. All efforts
should be made to make colonoscopies as comfortable as pos-
sible by paying full attention to adequate pain control and
sedation.
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